Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05518500 · ClinicalTrials.gov registry record · Phase 4

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

A Phase 4 study of Aging and Vaccine Response, sponsored by The Jackson Laboratory.

Recruiting
Registry status
Phase 4
Development phase
75
Enrollment target
1
Study location

NCT05518500: Recruiting Phase 4 study of Aging and Vaccine Response, sponsored by The Jackson Laboratory.

NCT05518500 is a Phase 4 study of Aging and Vaccine Response that is actively recruiting participants, run by The Jackson Laboratory. The registered enrollment target is 75 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05518500, a Phase 4 study of Aging and Vaccine Response, is actively recruiting participants, sponsored by The Jackson Laboratory.

RECRUITING
Registry status
Phase 4
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from participants at seven time-points across the study period. The study is not designed to assess safety or tolerability of the influenza vaccines administered as part of this study.

Primary Outcome

In year one, healthy older participants will receive Fluzone Quadrivalent HD vaccine. Longitudinal blood samples will be collected and influenza-specific antibody responses will be assessed. Change in antibody response will be measured using Hemagglutination Inhibition (HAI) from baseline to day 35 and day 180.

Interventions

  • BIOLOGICAL Flu Vaccine (Year 1)
  • BIOLOGICAL Flu Vaccine (Year 2)
  • BIOLOGICAL Flu Vaccine (Year 3)

Study Locations (1)

Connecticut

  • UConn Health, Center On Aging - Farmington

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2022-08-31
Est. Completion 2026-12-31
Phase Phase 4
The Jackson Laboratory

2 total trials

What NCT05518500 shows while recruiting

NCT05518500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Flu Vaccine (Year 1) is the first listed.

NCT05518500 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT05518500 about?

NCT05518500 is a clinical study titled "A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults". This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vac...

What is the current status of trial NCT05518500?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2022-08-31. Estimated completion is 2026-12-31.

What conditions does trial NCT05518500 study?

This clinical trial studies the following conditions: Aging, Vaccine Response, Influenza Vaccine, Dendritic Cell.

What interventions are being tested in trial NCT05518500?

The interventions under investigation include: Flu Vaccine (Year 1) (BIOLOGICAL), Flu Vaccine (Year 2) (BIOLOGICAL), Flu Vaccine (Year 3) (BIOLOGICAL).

Who is sponsoring clinical trial NCT05518500?

This trial is sponsored by The Jackson Laboratory, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05518500 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05518500's enrollment target sits among peer trials

75 115th of 262 higher than 146 of 262 other Aging trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05518500, the US trial registry maintained by the National Library of Medicine. NCT05518500 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.